DK3381933T3 - Muteiner af hngal og relaterede proteiner med affinitet til et givet mål - Google Patents

Muteiner af hngal og relaterede proteiner med affinitet til et givet mål Download PDF

Info

Publication number
DK3381933T3
DK3381933T3 DK18167640.4T DK18167640T DK3381933T3 DK 3381933 T3 DK3381933 T3 DK 3381933T3 DK 18167640 T DK18167640 T DK 18167640T DK 3381933 T3 DK3381933 T3 DK 3381933T3
Authority
DK
Denmark
Prior art keywords
affinity
related proteins
given target
hngal muteins
hngal
Prior art date
Application number
DK18167640.4T
Other languages
Danish (da)
English (en)
Inventor
Arne Skerra
Hyun-Jin Kim
Andreas Eichinger
Original Assignee
Technische Universität München
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universität München filed Critical Technische Universität München
Application granted granted Critical
Publication of DK3381933T3 publication Critical patent/DK3381933T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1037Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK18167640.4T 2008-06-24 2009-06-24 Muteiner af hngal og relaterede proteiner med affinitet til et givet mål DK3381933T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7517508P 2008-06-24 2008-06-24
EP09769304.8A EP2313430B1 (en) 2008-06-24 2009-06-24 Muteins of hngal and related proteins with affinity for a given target

Publications (1)

Publication Number Publication Date
DK3381933T3 true DK3381933T3 (da) 2020-08-03

Family

ID=41256028

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18167640.4T DK3381933T3 (da) 2008-06-24 2009-06-24 Muteiner af hngal og relaterede proteiner med affinitet til et givet mål

Country Status (7)

Country Link
US (2) US8420051B2 (OSRAM)
EP (2) EP2313430B1 (OSRAM)
JP (1) JP5711118B2 (OSRAM)
AU (1) AU2009264214B2 (OSRAM)
CA (1) CA2729322C (OSRAM)
DK (1) DK3381933T3 (OSRAM)
WO (1) WO2009156456A1 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1877428B1 (en) 2005-04-22 2011-03-16 University of Washington Cyanine- chlorotoxin conjugate and method for intra-operative visualization of cancer
BRPI0912683A2 (pt) 2008-05-15 2016-01-26 Transmolecular Inc tratamento de tumores metastáticos
WO2009156456A1 (en) * 2008-06-24 2009-12-30 Technische Universität München Muteins of hngal and related proteins with affinity for a given target
EP2510357B1 (en) 2009-12-07 2016-03-30 Pieris AG Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
CN106995493B (zh) 2010-02-04 2021-09-24 卫材公司 氯毒素多肽和结合物及其应用
ES2601182T3 (es) 2010-05-11 2017-02-14 Fred Hutchinson Cancer Research Center Variantes de clorotoxina, conjugados y métodos para su utilización
JP2013529907A (ja) 2010-05-24 2013-07-25 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Ngalタンパク質変異体及びその使用
CA2808392C (en) * 2010-08-16 2020-03-10 Pieris Ag Binding proteins for hepcidin
WO2012065978A1 (en) * 2010-11-15 2012-05-24 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
US9758554B2 (en) 2012-01-31 2017-09-12 Technische Universitaet Muenchen Muteins of α1m lipocalin and method of production therefor
US20140122522A1 (en) * 2012-10-26 2014-05-01 Google Inc. Method for providing users with help from their contacts while searching the web
WO2014081980A2 (en) 2012-11-21 2014-05-30 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
US10156559B2 (en) * 2012-12-10 2018-12-18 Fred Hutchinson Cancer Research Center Lipocalin fusion partners
CA2891557A1 (en) 2013-03-26 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
WO2015095553A1 (en) * 2013-12-20 2015-06-25 Nephrogenesis, Llc Methods and apparatus for kidney dialysis
BR112016027024A2 (pt) 2014-05-22 2017-10-31 Pieris Pharmaceuticals Gmbh polipeptídeos de ligação específica e seus usos
AU2016212087B2 (en) 2015-01-28 2019-11-07 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
CA2976687A1 (en) 2015-02-18 2016-08-25 Sanofi Novel proteins specific for pyoverdine and pyochelin
WO2016177802A1 (en) * 2015-05-04 2016-11-10 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
CA2980839C (en) 2015-05-04 2024-09-10 Pieris Pharmaceuticals Gmbh CD137 SPECIFIC PROTEINS
CA2982034A1 (en) 2015-05-18 2016-11-24 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
RU2754466C2 (ru) 2015-05-18 2021-09-02 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
EP3115066A1 (en) 2015-07-07 2017-01-11 Technische Universität München Novel psma-specific binding proteins
EP3115371A1 (en) * 2015-07-07 2017-01-11 Sanofi Fusion molecules
WO2017091850A1 (en) 2015-11-30 2017-06-08 Pieris Australia Pty Ltd. Novel anti-angiogenic fusion polypeptides
TW201725212A (zh) * 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
US12048732B2 (en) 2016-04-15 2024-07-30 Blaze Bioscience, Inc. Methods of treating breast cancer
JP2019526526A (ja) * 2016-05-04 2019-09-19 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングNavigo Proteins GmbH ペプチドリンカーを含む化学的部分の部位特異的カップリングのための標的化合物
WO2018044812A2 (en) 2016-08-29 2018-03-08 Fred Hutchinson Cancer Research Center Chelating platform for delivery of radionuclides

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5756825A (en) 1992-09-08 1998-05-26 Safavy; Ahmad Hydroxamic acid-based bifunctional chelating compounds
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
TR200003635T2 (tr) 1998-06-08 2001-04-20 F.Hoffmann-La Roche Ag Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması.
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
JP4336771B2 (ja) 2001-03-09 2009-09-30 モルフォシス アーゲー 血清アルブミン結合部分
US7118915B2 (en) 2001-09-27 2006-10-10 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
AU2003264100A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of a bilin-binding protein with affinity for a given target
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
US7517508B2 (en) 2004-07-26 2009-04-14 Isoray Medical, Inc. Method of separating and purifying Yttrium-90 from Strontium-90
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
US20070191272A1 (en) 2005-09-27 2007-08-16 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
WO2009156456A1 (en) * 2008-06-24 2009-12-30 Technische Universität München Muteins of hngal and related proteins with affinity for a given target

Also Published As

Publication number Publication date
US8420051B2 (en) 2013-04-16
EP2313430B1 (en) 2018-05-02
EP3381933B1 (en) 2020-06-03
CA2729322C (en) 2020-05-26
EP2313430A1 (en) 2011-04-27
EP3381933A1 (en) 2018-10-03
AU2009264214B2 (en) 2013-06-06
JP5711118B2 (ja) 2015-04-30
JP2011525354A (ja) 2011-09-22
AU2009264214A1 (en) 2009-12-30
US20110262353A1 (en) 2011-10-27
US20130316962A1 (en) 2013-11-28
WO2009156456A1 (en) 2009-12-30
CA2729322A1 (en) 2009-12-30
US9040020B2 (en) 2015-05-26

Similar Documents

Publication Publication Date Title
DK3381933T3 (da) Muteiner af hngal og relaterede proteiner med affinitet til et givet mål
DK3202779T3 (da) Hgh polypeptider med langtidsvirkning og anvendelser deraf
DK2102398T3 (da) Fremgangsmåde til fremstilling af en ankelsok og ankelsok opnået derved
DK2139987T3 (da) Fremgangsmåder til proteinfremstilling med anti-senescens-forbindelser
ATE524493T1 (de) Exendin-fusionsproteine
DK2235044T3 (da) Nye polypeptider med bindingsaffinitet til HER2
DK3339445T3 (da) Interleukin -13 bindende proteiner
DK2147096T3 (da) Modificerede faktor-VII-polypeptider og anvendelser deraf
DK3081315T3 (da) Fremgangsmåde og system til sortering af fødevarer
BRPI0906722A2 (pt) Métodos e composições usando polipeptídeos de fusão klotho-fgf
DE602007011923D1 (de) Hepatocytenwachstumsfaktor-(hgf-)bindungsproteine
DK3118221T3 (da) Proteiner
DK2046819T3 (da) Fremgangsmåder til forøgelse af secernering af polypeptider med biologisk aktivitet
DK3067064T3 (da) Modificerede rsv-f-proteiner og fremgangsmåder til anvendelse deraf
DK2099823T4 (da) Målbindingsmiddelvarianter og anvendelser deraf
DK2046362T3 (da) Formulering omfattende valleprotein og hydrolysater til forbedring af muskelrekuperation
DK2222675T3 (da) 5-anilinoimidazopyridiner og fremgangsmåder til deres anvendelse
DK3092901T3 (da) Quinolonanaloger og fremgangsmåder relateret dertil
DK2252633T3 (da) Anti-TrkA antistoffer og derivater deraf
DK2135603T3 (da) Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet
DK2990798T3 (da) Muteiner af human lipocalin 2 (lcn2, hngal) med affinitet for et specifikt mål
NO345032B1 (no) Kulestempel-styreanordninger og fremgangsmåter for bruk
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
DK2222314T3 (da) Anvendelser og midler til opnåelse af bronchorelaxation
DK2228629T3 (da) System og fremgangsmåde til bestemmelse af positionen af en motordel